100 completed, 25 recruiting, 24 terminated, 9 withdrawn. 174 Phase 1, 40 Phase 2.
Follow Emory University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III | Phase 1 / Phase 2 | Not yet recruiting | Emory University | 12 | 2027-01-01 | 2026-05-08 |
| Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life Psilocybin (Usona Institute) - Aging, Longevity | Phase 1 | Not yet recruiting | Charles Raison | 50 | 2026-12-01 | 2026-10-13 |
| Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment - Human Papilloma Virus, Human Immunodeficiency Virus | Phase 1 | Not yet recruiting | Emory University | 9 | 2026-12-01 | 2026-08-18 |
| Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab - Osteosarcoma, Pulmonary Recurrence of Osteosarcoma | Phase 1 | Recruiting | Emory University | 12 | 2026-10-01 | 2026-09-30 |
| Digital STEADI Efficacy Digital STEADI-1, STEADI Standard of Care, Digital STEADI-2 - Fall, Mild Cognitive Impairment (MCI) | Phase 1 / Phase 2 | Recruiting | Friendi.fi Corporation | 300 | 2026-09-04 | 2026-10-01 |
| A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer axelopran, Pembolizumab - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 1 / Phase 2 | Not yet recruiting | Glycyx Therapeutics | 18 | 2026-07-15 | 2026-07-15 |
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| Safety and Tolerability Trial of Psilocybin in Healthy Older Adults Psilocybin (Usona Institute) - Healthy Volunteer, Older Adults (65-85 Years) | Phase 1 | Recruiting | University of Colorado, Denver | 40 | 2026-04-01 | 2026-09-16 |
| Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma Tegavivint, Gemcitabine - Osteosarcoma Recurrent, Osteosarcoma in Children | Phase 1 | Recruiting | Emory University | 24 | 2026-01-22 | 2026-10-19 |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography - Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm | Phase 1 | Recruiting | Emory University | 15 | 2025-10-14 | 2026-03-02 |
| Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS) Ventrix Bio Extracellular Matrix - Hypoplastic Left Heart Syndrome | Phase 1 | Not yet recruiting | Emory University | 12 | 2025-08-01 | 2025-03-10 |
| A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM) Allogeneic Neonatal mesenchymal stromal cells (nMSCs) - Dilated Cardiomyopathy | Phase 1 | Recruiting | Emory University | 36 | 2025-07-14 | 2026-06-26 |
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| Atovaquone Combined With Radiation in Children With Malignant Brain Tumors Atovaquone, Radiation Therapy - High-grade Glioma, Medulloblastoma | Phase 1 | Recruiting | Emory University | 18 | 2025-03-28 | 2026-08-03 |
| A/Texas Flu Challenge Influenza Virus influenza A H3N2 strain - Influenza | Phase 1 | Recruiting | Emory University | 50 | 2025-02-04 | 2026-03-03 |
| ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer ProAgio Dose Levels (DL) 1,2,3,4, ProAgio Dose Expansion - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | ProDa BioTech, LLC | 51 | 2024-08-20 | 2026-08-31 |
| Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients MT218 injection - MRI Scan | Phase 1 / Phase 2 | Recruiting | Songqi Gao | 12 | 2024-07-25 | 2025-12-19 |
| Identifying Personalized Brain States Predicting Residual Corticospinal Tract Output After Stroke Single-pulse TMS - Stroke | Phase 1 | Recruiting | University of Texas at Austin | 20 | 2024-02-02 | 2025-02-10 |
| Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study TAF/EVG rectal insert, Matching placebo rectal insert - Safety Issues | Phase 1 | Completed | Eastern Virginia Medical School | 21 | 2024-01-16 | 2025-07-25 |
Showing 20 of 174. Sign in to see all of them.
Multiple Myeloma (10) · Neoplasms (10) · Lung Neoplasms (9) · Pancreatic Neoplasms (8) · Acquired Immunodeficiency Syndrome (7) · Brain Neoplasms (7) · Osteosarcoma (7) · Squamous Cell Carcinoma of Head and Neck (7) · Anemia, Sickle Cell (6) · Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (6) · Colorectal Neoplasms (6) · Head and Neck Neoplasms (6) · Neuroblastoma (6) · Recurrence (6)
Bortezomib (9) · Everolimus (8) · Cyclophosphamide (7) · Dexamethasone (7) · Nivolumab (7) · Radiosurgery (7) · pembrolizumab (7) · Calcium Dobesilate (6) · Magnetic Resonance Spectroscopy (6) · Radiation (6) · CTLA-4 Antigen (5) · Gemcitabine (5) · Ipilimumab (5) · Radiotherapy (5) · Carboplatin (4)
United States (166) · Bangladesh (1) · Canada (1) · Switzerland (1) · Zambia (1)
Kristin Higgins, MD (4) · Bassel El-Rayes, MD (3) · Jonathon Cohen, MD, MS (3) · Nabil F. Saba, MD (3) · Nadine Rouphael, MD (3) · Sagar Lonial, MD (3) · Suresh Ramalingam, MD (3) · Thomas Cash, MD, MSc (3) · Colleen Kelley, MD, MPH (2) · Conor Steuer, MD (2) · Dong Shin, MD (2) · John Horan, MD (2) · John Kauh, MD (2) · Jonathan Kaufman, MD (2) · Kelly Goldsmith, MD (2)
PMID 31401903, PMID 18278987, PMID 18547438, PMID 21346146, PMID 21456040, PMID 21717276, PMID 22409311, PMID 22535574, PMID 22766415, PMID 23208880, PMID 23468538, PMID 23471421, PMID 23595643, PMID 23838996, PMID 24085777, PMID 24285617, PMID 24491070, PMID 25103371, PMID 25188543, PMID 26248505, PMID 27475674, PMID 28666680, PMID 28972191, PMID 29451701, PMID 30428930, PMID 30610196, PMID 31876107, PMID 32051147, PMID 32384147, PMID 32391156, PMID 32704173, PMID 33029623, PMID 34392411, PMID 34653525, PMID 36180329, PMID 36189324, PMID 37910603, PMID 38407630, PMID 38527291, PMID 38797190, PMID 38976035, PMID 39187595, PMID 39589151, PMID 40296503, PMID 40439767, PMID 40578814, PMID 40705333, PMID 40973049, PMID 41379553, PMID 42549972
P30CA138292 (33), P50CA217691 (2), 1RF1AG051514 (1), 2016 (1), K23HL133446 (1), K24AT009893 (1), KL2TR000455 (1), P01HL086773 (1), P50CA128613 (1), R01CA112643 (1), R01CA262123 (1), R01HL095479 (1), R01HL146668 (1), R01MH062717 (1), R01NR004340 (1)